Moderna, Inc. (MRNA) shares plummeted 10.10% in intraday trading on Friday following the release of its second-quarter 2025 financial results and a series of announcements that raised concerns about the company's near-term prospects. The biotechnology giant, known for its mRNA technology and COVID-19 vaccine, reported figures that beat analyst expectations but simultaneously delivered news that rattled investors.

While Moderna reported Q2 revenue of $142 million, surpassing the analyst consensus estimate of $112.9 million, and posted a smaller-than-expected loss of $2.13 per share compared to the anticipated $2.97 loss, the company's forward-looking statements overshadowed these positive results. Moderna lowered its 2025 revenue forecast to a range of $1.5 billion to $2.2 billion, cutting $300 million from the previous high-end projection. This reduction reflects ongoing challenges in the post-pandemic vaccine market and heightened uncertainty about future demand.

Adding to investor concerns, Moderna announced plans to reduce its global workforce by approximately 10% by the end of the year, shrinking to under 5,000 employees. This move, part of the company's efforts to trim operating expenses, signals a strategic shift as Moderna navigates a rapidly evolving healthcare landscape. The company aims to cut operating costs by $400 million in 2025, bringing them down to $5.9 billion to $6.1 billion. Despite these cost-saving measures, the market's focus remains on the top-line pressures facing the company as it transitions from its pandemic-era success to a more challenging business environment.